| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Rapid chemotherapy-induced acute endothelial progenitor cell mobilization: implications for antiangiogenic drugs as chemosensitizing agents.
|
Cancer Cell
|
2008
|
4.51
|
|
2
|
Genetic heterogeneity of the vasculogenic phenotype parallels angiogenesis; Implications for cellular surrogate marker analysis of antiangiogenesis.
|
Cancer Cell
|
2005
|
3.74
|
|
3
|
Vaccination of metastatic melanoma patients with autologous tumor-derived heat shock protein gp96-peptide complexes: clinical and immunologic findings.
|
J Clin Oncol
|
2002
|
2.57
|
|
4
|
Human acute leukemia cells injected in NOD/LtSz-scid/IL-2Rgamma null mice generate a faster and more efficient disease compared to other NOD/scid-related strains.
|
Int J Cancer
|
2008
|
2.45
|
|
5
|
Metronomic cyclophosphamide and capecitabine combined with bevacizumab in advanced breast cancer.
|
J Clin Oncol
|
2008
|
2.10
|
|
6
|
Validation of a standardized method for enumerating circulating endothelial cells and progenitors: flow cytometry and molecular and ultrastructural analyses.
|
Clin Cancer Res
|
2009
|
2.00
|
|
7
|
Optimal biologic dose of metronomic chemotherapy regimens is associated with maximum antiangiogenic activity.
|
Blood
|
2005
|
1.80
|
|
8
|
Circulating endothelial cells. Biomarker of vascular disease.
|
Thromb Haemost
|
2005
|
1.73
|
|
9
|
Circulating endothelial-cell kinetics and viability predict survival in breast cancer patients receiving metronomic chemotherapy.
|
Blood
|
2006
|
1.69
|
|
10
|
Rituximab and subcutaneous 2-chloro-2'-deoxyadenosine combination treatment for patients with Waldenstrom macroglobulinemia: clinical and biologic results of a phase II multicenter study.
|
J Clin Oncol
|
2010
|
1.63
|
|
11
|
Autologous peripheral blood stem cell transplantation for myocardial regeneration: a novel strategy for cell collection and surgical injection.
|
Ann Thorac Surg
|
2004
|
1.48
|
|
12
|
Increased mean corpuscular volume of red blood cells predicts response to metronomic capecitabine and cyclophosphamide in combination with bevacizumab.
|
Breast
|
2012
|
1.39
|
|
13
|
Fat Grafting after Invasive Breast Cancer: A Matched Case-Control Study.
|
Plast Reconstr Surg
|
2017
|
1.38
|
|
14
|
The white adipose tissue used in lipotransfer procedures is a rich reservoir of CD34+ progenitors able to promote cancer progression.
|
Cancer Res
|
2011
|
1.37
|
|
15
|
Continuous infusion of endostatin inhibits differentiation, mobilization, and clonogenic potential of endothelial cell progenitors.
|
Clin Cancer Res
|
2003
|
1.23
|
|
16
|
Contribution of granulocyte colony-stimulating factor to the acute mobilization of endothelial precursor cells by vascular disrupting agents.
|
Cancer Res
|
2009
|
1.20
|
|
17
|
High-Dose celecoxib and metronomic "low-dose" cyclophosphamide is an effective and safe therapy in patients with relapsed and refractory aggressive histology non-Hodgkin's lymphoma.
|
Clin Cancer Res
|
2006
|
1.18
|
|
18
|
The extracellular nucleotide UTP is a potent inducer of hematopoietic stem cell migration.
|
Blood
|
2006
|
1.17
|
|
19
|
Circulating endothelial cells as biomarkers in clinical oncology.
|
Microvasc Res
|
2010
|
1.17
|
|
20
|
Targeting activin receptor-like kinase 1 inhibits angiogenesis and tumorigenesis through a mechanism of action complementary to anti-VEGF therapies.
|
Cancer Res
|
2011
|
1.13
|
|
21
|
Endothelial progenitor cells are cellular hubs essential for neoangiogenesis of certain aggressive adenocarcinomas and metastatic transition but not adenomas.
|
Proc Natl Acad Sci U S A
|
2008
|
1.13
|
|
22
|
Host response to short-term, single-agent chemotherapy induces matrix metalloproteinase-9 expression and accelerates metastasis in mice.
|
Cancer Res
|
2011
|
1.12
|
|
23
|
Predictive Potential of Angiogenic Growth Factors and Circulating Endothelial Cells in Breast Cancer Patients Receiving Metronomic Chemotherapy Plus Bevacizumab.
|
Clin Cancer Res
|
2009
|
1.07
|
|
24
|
Extracellular nucleotides are potent stimulators of human hematopoietic stem cells in vitro and in vivo.
|
Blood
|
2004
|
1.07
|
|
25
|
Complementary populations of human adipose CD34+ progenitor cells promote growth, angiogenesis, and metastasis of breast cancer.
|
Cancer Res
|
2013
|
1.05
|
|
26
|
Microvessel density, a surrogate marker of angiogenesis, is significantly related to survival in multiple myeloma patients.
|
Br J Haematol
|
2002
|
1.04
|
|
27
|
Anti-angiogenic treatment of breast cancer using metronomic low-dose chemotherapy.
|
Breast
|
2005
|
1.02
|
|
28
|
Cellular and molecular surrogate markers to monitor targeted and non-targeted antiangiogenic drug activity and determine optimal biologic dose.
|
Curr Cancer Drug Targets
|
2005
|
1.02
|
|
29
|
The biguanides metformin and phenformin inhibit angiogenesis, local and metastatic growth of breast cancer by targeting both neoplastic and microenvironment cells.
|
Int J Cancer
|
2014
|
1.02
|
|
30
|
Circulating endothelial cells as a novel marker of angiogenesis.
|
Adv Exp Med Biol
|
2003
|
1.01
|
|
31
|
Assessing tumor angiogenesis: increased circulating VE-cadherin RNA in patients with cancer indicates viability of circulating endothelial cells.
|
Cancer Res
|
2004
|
1.00
|
|
32
|
International expert consensus on primary systemic therapy in the management of early breast cancer: highlights of the Fourth Symposium on Primary Systemic Therapy in the Management of Operable Breast Cancer, Cremona, Italy (2010).
|
J Natl Cancer Inst Monogr
|
2011
|
1.00
|
|
33
|
Paradoxic effects of metformin on endothelial cells and angiogenesis.
|
Carcinogenesis
|
2014
|
1.00
|
|
34
|
The transactivating isoforms of p63 are overexpressed in high-grade follicular lymphomas independent of the occurrence of p63 gene amplification.
|
J Pathol
|
2005
|
0.97
|
|
35
|
Low-dose metronomic chemotherapy: from past experience to new paradigms in the treatment of cancer.
|
Drug Discov Today
|
2012
|
0.95
|
|
36
|
On the origin and nature of elevated levels of circulating endothelial cells after treatment with a vascular disrupting agent.
|
J Clin Oncol
|
2006
|
0.95
|
|
37
|
Molecular and functional analysis of the stem cell compartment of chronic myelogenous leukemia reveals the presence of a CD34- cell population with intrinsic resistance to imatinib.
|
Blood
|
2009
|
0.94
|
|
38
|
Metronomic chemotherapy combined with bevacizumab and erlotinib in patients with metastatic HER2-negative breast cancer: clinical and biological activity.
|
Clin Breast Cancer
|
2012
|
0.94
|
|
39
|
Circulating endothelial cells as a therapeutic marker for thalidomide in combined therapy with chemotherapy drugs in a human prostate cancer model.
|
BJU Int
|
2007
|
0.91
|
|
40
|
Therapeutic effect of lenalidomide in a novel xenograft mouse model of human blastic NK cell lymphoma/blastic plasmacytoid dendritic cell neoplasm.
|
Clin Cancer Res
|
2011
|
0.90
|
|
41
|
Prognostic value of CD109+ circulating endothelial cells in recurrent glioblastomas treated with bevacizumab and irinotecan.
|
PLoS One
|
2013
|
0.89
|
|
42
|
Hepatocyte-conditioned medium sustains endothelial differentiation of human hematopoietic-endothelial progenitors.
|
Hepatology
|
2007
|
0.89
|
|
43
|
Miniaturized FISH for screening of onco-hematological malignancies.
|
Biotechniques
|
2010
|
0.88
|
|
44
|
Sex-related efficiency in NSG mouse engraftment.
|
Blood
|
2010
|
0.88
|
|
45
|
Evidence of distinct tumour-propagating cell populations with different properties in primary human hepatocellular carcinoma.
|
PLoS One
|
2011
|
0.88
|
|
46
|
Residual dormant cancer stem-cell foci are responsible for tumor relapse after antiangiogenic metronomic therapy in hepatocellular carcinoma xenografts.
|
Lab Invest
|
2012
|
0.87
|
|
47
|
Circulating perivascular progenitors: a target of PDGFR inhibition.
|
Int J Cancer
|
2011
|
0.86
|
|
48
|
Infusional fluorouracil, epirubicin, and cisplatin followed by weekly paclitaxel plus bevacizumab in locally advanced breast cancer with unfavorable prognostic features.
|
Anticancer Drugs
|
2009
|
0.86
|
|
49
|
EPO receptor gain-of-function causes hereditary polycythemia, alters CD34 cell differentiation and increases circulating endothelial precursors.
|
PLoS One
|
2010
|
0.85
|
|
50
|
Spontaneous cell fusion of acute leukemia cells and macrophages observed in cells with leukemic potential.
|
Neoplasia
|
2012
|
0.85
|
|
51
|
Amelioration of glucose control mobilizes circulating pericyte progenitor cells in type 2 diabetic patients with microangiopathy.
|
Exp Diabetes Res
|
2012
|
0.85
|
|
52
|
Circulating endothelial cells and circulating endothelial progenitors.
|
Recent Results Cancer Res
|
2012
|
0.85
|
|
53
|
Skeletal muscle differentiation potential of human adult bone marrow cells.
|
Exp Cell Res
|
2004
|
0.84
|
|
54
|
Tailored therapy of adult acute leukaemia in Jehovah's Witnesses: unjustified reluctance to treat.
|
Eur J Haematol
|
2004
|
0.84
|
|
55
|
SP4, a novel anti-cyclin D1 rabbit monoclonal antibody, is a highly sensitive probe for identifying mantle cell lymphomas bearing the t(11;14)(q13;q32) translocation.
|
Appl Immunohistochem Mol Morphol
|
2005
|
0.82
|
|
56
|
Human haemato-endothelial precursors: cord blood CD34+ cells produce haemogenic endothelium.
|
PLoS One
|
2012
|
0.82
|
|
57
|
Cyclin D3 immunoreactivity in gastrointestinal stromal tumors is independent of cyclin D3 gene amplification and is associated with nuclear p27 accumulation.
|
Mod Pathol
|
2003
|
0.82
|
|
58
|
Stem cell plasticity: time for a reappraisal?
|
Haematologica
|
2005
|
0.82
|
|
59
|
Circulating endothelial cells as biomarkers for angiogenesis in tumor progression.
|
Front Biosci (Schol Ed)
|
2009
|
0.81
|
|
60
|
In vitro and in vivo hematopoietic potential of human stem cells residing in muscle tissue.
|
Exp Hematol
|
2002
|
0.81
|
|
61
|
Safety, tolerability and biological effects of long-term metronomic administration of non-cytotoxic anti-angiogenic agents.
|
Oncology
|
2010
|
0.80
|
|
62
|
Circulating endothelial cell number and viability are reduced by exposure to high altitude.
|
Endothelium
|
2008
|
0.80
|
|
63
|
Chronic idiopathic myelofibrosis: independent prognostic importance of bone marrow microvascular density evaluated by CD105 (endoglin) immunostaining.
|
Mod Pathol
|
2004
|
0.79
|
|
64
|
Simultaneous characterization of progenitor cell compartments in adult human liver.
|
Cytometry A
|
2010
|
0.79
|
|
65
|
If it is in the marrow, is it also in the blood? An analysis of 1,000 paired samples from patients with B-cell non-Hodgkin lymphoma.
|
BMC Cancer
|
2010
|
0.79
|
|
66
|
Circulating endothelial progenitor cells.
|
N Engl J Med
|
2005
|
0.79
|
|
67
|
Mammaglobin expression in leukapheresis products is a predictive marker of poor prognosis in women with high-risk breast cancer.
|
Clin Cancer Res
|
2004
|
0.79
|
|
68
|
Lenalidomide for multiple myeloma.
|
N Engl J Med
|
2012
|
0.79
|
|
69
|
zeta-Crystallin is a bcl-2 mRNA binding protein involved in bcl-2 overexpression in T-cell acute lymphocytic leukemia.
|
FASEB J
|
2010
|
0.79
|
|
70
|
Chlorambucil in combination with induction and maintenance rituximab is feasible and active in indolent non-Hodgkin's lymphoma.
|
Br J Haematol
|
2003
|
0.79
|
|
71
|
Circulating endothelial cells as biomarkers for patients receiving bevacizumab.
|
Lancet Oncol
|
2011
|
0.79
|
|
72
|
Angiogenic cells, macroparticles and RNA transcripts in laparoscopic vs open surgery for colorectal cancer.
|
Cancer Biol Ther
|
2010
|
0.78
|
|
73
|
Cell cycle regulators in multiple myeloma: prognostic implications of p53 nuclear accumulation.
|
Hum Pathol
|
2003
|
0.78
|
|
74
|
Immunoglobulin heavy chain genes somatic hypermutations and chromosome 11q22-23 deletion in classic mantle cell lymphoma: a study of the Swiss Group for Clinical Cancer Research.
|
Br J Haematol
|
2004
|
0.78
|
|
75
|
Angiogenesis occurs in hairy cell leukaemia (HCL) and in NOD/SCID mice transplanted with the HCL line Bonna-12.
|
Br J Haematol
|
2003
|
0.77
|
|
76
|
Circulating endothelial cells (CECs) and progenitors (CEPs) in severe haemophiliacs with different clinical phenotype.
|
Br J Haematol
|
2008
|
0.77
|
|
77
|
Cyclin D3 immunoreactivity in follicular lymphoma is independent of the t(6;14)(p21.1;q32.3) translocation or cyclin D3 gene amplification and is correlated with histologic grade and Ki-67 labeling index.
|
Int J Cancer
|
2004
|
0.77
|
|
78
|
Strategies to investigate circulating endothelial cells in cancer.
|
Pathophysiol Haemost Thromb
|
2005
|
0.76
|
|
79
|
Chimerism of the transplanted heart.
|
N Engl J Med
|
2002
|
0.75
|
|
80
|
Blood-based biomarkers for the optimization of anti-angiogenic therapies.
|
Cancers (Basel)
|
2010
|
0.75
|
|
81
|
Immunoreactivity for cyclin D1 is a reliable marker of gene aberration in plasma cell myeloma but does not specify patients prognosis.
|
Leuk Res
|
2008
|
0.75
|
|
82
|
Functional and kinetic characterization of granulocyte colony-stimulating factor-primed CD34- human stem cells.
|
Br J Haematol
|
2003
|
0.75
|
|
83
|
Stromal cell-derived factor-1α promotes endothelial colony forming cell migration through the Ca2+-dependent activation of the extracellular signal-regulated kinase 1/2 and phosphoinositide 3-kinase/AKT pathways.
|
Stem Cells Dev
|
2017
|
0.75
|
|
84
|
Stroma cells: a novel target of herceptin activity.
|
Clin Cancer Res
|
2003
|
0.75
|
|
85
|
Erratum: The pan-class I phosphatidyl-inositol-3 kinase inhibitor NVP-BKM120 demonstrates anti-leukemic activity in acute myeloid leukemia.
|
Sci Rep
|
2016
|
0.75
|